Koç Healthcare and American Hospital’s MDLinx coverage

Our international media relations work for Koç Healthcare brought İzmir American Hospital’s oncology expertise to MDLinx’s physician readership. Assoc. Prof. Elvina Almuradova contributed four distinct expert quotations to an article on HER2 testing in breast cancer, published on 18 November 2026. One comment also featured at the opening, while the first reference to her name linked directly to her official hospital profile.
This was the first editorial result secured through expert commentary within Koç Healthcare’s UK communications programme. The UK-focused programme gained visibility in a US-based medical publication for physicians. For us, the value lay in American Hospital’s expertise contributing to the discussion of a current clinical question.

The strategy: match the editorial question with relevant expertise
A strong opportunity in healthcare communications begins with understanding the question a publication is exploring. MDLinx was examining the limits of HER2 testing in breast cancer and the potential of emerging approaches. HER2 is a protein involved in the growth of some cancer cells; identifying its level accurately can matter when particular treatments are considered.
Almuradova’s work in breast cancer and targeted therapies matched that focus. We proposed her as an expert source. When the publication requested comment, we shared the questions with the physician and hospital team and coordinated the development of the responses. We built the contribution around the clinical meaning of the tests, their limitations and the questions research has yet to answer.
Four comments that built a coherent clinical perspective
The published comments addressed different parts of the same problem. They moved from interpreting a test result to differences between tumour sites, emerging imaging techniques and the evidence needed before adoption. The short extracts below come from the original English responses prepared for this work; these comments also appeared in the MDLinx article.
1. Why a small scoring difference can matter
“Even small differences in staining or scoring can lead to very different tumor classifications and even affect a patient’s eligibility for a particular treatment.”
Almuradova highlighted the difficulty of distinguishing low HER2 expression from an undetectable level. The contribution connected a technical laboratory issue with a clinical decision. MDLinx also selected part of this comment for its opening “Industry Buzz” panel.
2. Why reassessment can become relevant
“When metastatic tissue is available, reassessing HER2 and comparing it with the primary tumor result can change treatment selection.”
The second comment addressed differences between an initial tumour sample and tissue obtained after cancer has spread. It explained the limits of treating a test result as a permanent label. This added an expert perspective on why the timing and site of a sample can matter.
3. What a new imaging approach could reveal
“HER2-targeted PET can reveal, in a single scan, the extent to which various lesions in metastatic breast cancer take up an imaging agent that binds to HER2.”
PET is an imaging method used to show particular biological processes in the body. This comment explained the potential of the investigational HER2-targeted approach to examine several tumour sites together. It connected the technology with a concrete clinical question a reader could understand.
4. Keeping promise in proportion to the evidence
“Many of these technologies have great promise, but they are not yet ready to be used in clinical practice.”
The final comment supplied an essential qualification. Almuradova called for standardised methods and prospective clinical studies, which follow patients forward over time. Her contribution maintained the distinction between research potential and an established role in clinical practice.

The result: a visible, traceable editorial contribution for American Hospital
The verified output was four distinct expert quotations, one highlighted opening comment and a direct link to the official physician profile. The opening extract repeated part of the first comment in the body, so it does not count as a fifth expert quotation. The name attribution and hospital profile gave readers a way to examine the source of the contribution.
For Koç Healthcare and American Hospital, this was a concrete result from media relations built around relevant clinical expertise. The published contribution and link are verifiable; readership, referral traffic and changes in search rankings were not measured in this case. Its strength lay in matching the right specialist with a relevant question and securing a clear place for that expertise in an independent publication’s reporting.
Talk to us about connecting your organisation’s expertise with international media.
Participate in the World's Most Prestigious Publications and Platforms
Our clients earn visibility across respected publications and platforms worldwide. Each programme is planned around its target market, news value, placement type and measurement method. Outcomes vary by campaign scope and independent editorial decisions.















